<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371501</url>
  </required_header>
  <id_info>
    <org_study_id>HARECCTR0500059</org_study_id>
    <nct_id>NCT00371501</nct_id>
  </id_info>
  <brief_title>Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus</brief_title>
  <official_title>Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tuen Mun Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can
      reduce the progression of subclinical atherosclerosis in patients with systemic lupus
      erythematosus (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study if aspirin and statins (lipid-lowering agents) can reduce the progression of
      subclinical atherosclerosis in patients with systemic lupus erythematosus. Subclinical
      atherosclerosis is assessed by ultrasound study of the carotid vessels and CT scan of the
      coronary arteries for calcium scores. Blood markers of endothelial activation will also be
      studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial activation markers</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>carotid intima media thickness</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary Agatston score</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic events</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Thromboembolism</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>treatment arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10mg/day</description>
    <arm_group_label>treatment arm 1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one tablet/day</description>
    <arm_group_label>Treatment arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>80mg/day</description>
    <arm_group_label>treatment arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>treatment arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Fulfillment of at least 4 of the American College of Rheumatology (ACR) criteria for
             SLE

          3. Presence of any two of the following risk factors:

               -  SLE duration of &gt;= 5 years

               -  Postmenopausal

               -  Age &gt;= 40 years

               -  Diabetes mellitus

               -  Hypertension (140/90 mmHg)

               -  Serum low density lipoprotein (LDL) level &gt;= 2.6 mmol/L or total cholesterol &gt;=
                  5.5 mmol/L

               -  Obesity (body mass index &gt;= 27 kg/m2)

               -  Chronic current smoker

               -  Positive antiphospholipid antibodies

               -  Renal function impairment

               -  Persistent proteinuria &gt;= 1 gm/day for &gt;= 6 months

          4. Informed consent obtained

        Exclusion Criteria:

          1. Patients with known allergy to aspirin, or any other non-steroidal anti-inflammatory
             drugs (NSAIDs), or statins

          2. Patient with a history of severe gastrointestinal intolerance to aspirin (e.g.,
             gastrointestinal bleeding) or other NSAIDs

          3. Patients with history of arterial or venous thromboembolism

          4. Patients receiving aspirin or other anti-platelet agents

          5. Patients receiving long-term non-aspirin NSAIDs

          6. Patients receiving anticoagulation therapy (e.g., warfarin)

          7. Patients with history of intolerance or allergy to the statins

          8. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CC Mok, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Tuen Mun Hospital, Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>CC Mok</name_title>
    <organization>Tuen Mun Hospital, Hong Kong</organization>
  </responsible_party>
  <keyword>lupus</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>thrombosis</keyword>
  <keyword>statin</keyword>
  <keyword>lipid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

